Group 1 - The application for Ipilimumab injection by Bristol-Myers Squibb Holdings Pharma, Ltd. has been accepted, with acceptance number JTS2600018, on February 7, 2026 [1] - Ipilimumab is classified as a biological product and is being registered for import [1] - Shanghai Junshi Biosciences Co., Ltd. is a key player in this application, alongside Bristol-Myers Squibb [1] Group 2 - Shanghai Junshi Biosciences Co., Ltd. was established on June 26, 2014, and is a medium-sized foreign-invested enterprise with a registered capital of 74 million RMB [1] - The company has 774 insured employees and is located at 1289 Yishan Road, Xuhui District, Shanghai [1] - The sole shareholder of Shanghai Junshi Biosciences is Junshi Biosciences Co., Ltd., which holds 100% of the shares [1]
药物受理最新动态：Bristol-Myers Squibb Holdings Pharma,...
Xin Lang Cai Jing·2026-02-06 23:46